Skip to main content
Mesoblast Limited (ASX:MSB)
Australia flag Australia · Delayed Price · Currency is AUD
2.300
+0.120 (5.50%)
At close: Mar 6, 2026

Mesoblast Revenue

Mesoblast had revenue of $51.34M USD in the half year ending December 31, 2025, with 1,415.41% growth. This brings the company's revenue in the last twelve months to $65.38M, up 1,053.16% year-over-year. In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth.

Revenue (ttm)
$65.38M
Revenue Growth
+1,053.16%
P/S Ratio
30.29
Revenue / Employee
$807.21K
Employees
81
Market Cap
2.97B AUD

Revenue Chart

* This company reports financials in USD.

History

Fiscal Year End Revenue Change Growth
Jun 30, 202517.20M11.30M191.39%
Jun 30, 20245.90M-1.60M-21.32%
Jun 30, 20237.50M-2.71M-26.54%
Jun 30, 202210.21M2.78M37.36%
Jun 30, 20217.43M-24.72M-76.88%
Jun 30, 2020 Pro Pro Pro
Jun 30, 2019 Pro Pro Pro
Jun 30, 2018 Pro Pro Pro
Jun 30, 2017 Pro Pro Pro
Jun 30, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Telix Pharmaceuticals 1.21B
Neuren Pharmaceuticals 64.65M
PYC Therapeutics 20.56M
Clarity Pharmaceuticals 10.58M
Opthea -20.12K
Immutep 7.92M
Clinuvel Pharmaceuticals 96.30M
Racura Oncology 3.48M
Revenue Rankings

Mesoblast News

More News